← Eichor
Condition: Relapsed And Or Refractory Multiple Myeloma Rrmm Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed And Or Refractory Multiple Myeloma Rrmm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · 266 location(s) · Celgene · NCT05519085A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Partici
Phase 2 · 34 location(s) · Sanofi · NCT06356571A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1 · 3 location(s) · Zhejiang University · NCT06644118Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Particip
Phase 3 · 166 location(s) · AbbVie · NCT06158841Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed
Phase 2 · 52 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06297226SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refrac
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06622005Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003568A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or
Phase 3 · 141 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06615479A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care C
Phase 3 · 20 location(s) · Regeneron Pharmaceuticals · NCT07222761Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003555Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/Phase 2 · 7 location(s) · YOUNGIL KOH · NCT06645678Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Phase 1/Phase 2 · 26 location(s) · Sanofi · NCT0464300218F-Fluciclovine PET/CT in Multiple Myeloma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06103838A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 · 69 location(s) · Janssen Research & Development, LLC · NCT07266441A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Ef
Phase 3 · 1 location(s) · Shandong New Time Pharmaceutical Co., LTD · NCT07579234A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relap
Phase 1 · 43 location(s) · Pfizer · NCT06215118Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refracto
Phase 1/Phase 2 · 1 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT06484829In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07715630A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT05759793A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 10 location(s) · ModernaTX, Inc. · NCT07116616Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.